Results for this period
Third quarter1 July 2025 to 31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Shipments to domestic synchrotron radiation facilities and shipments of high-margin products lifted revenue and profit in the Optical Business. CellPet® and automated cell culture systems also contributed to revenue. In the Other Business, however, sales of the core products were limited to 1 unit for a domestic customer, and higher raw material prices reduced margins. In the Life Science and Equipment Development Business, selling, general and administrative expenses increased, mainly due to higher research and development expenses.
None ("There are no applicable matters.")
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 July 2025 to 31 March 2026 |
| Net Sales | ¥1,040 million (YoY +7.5%) |
| Operating profit | ¥-239 million |
| Ordinary income | ¥-232 million |
| Profit attributable to owners of the parent | ¥-176 million |
| Net income per share | △29.95 yen |
| Equity ratio | End of the current fiscal period 75.7 / End of previous period 75.3 |
| Total assets | ¥3,456 million |
| Net assets | ¥2,617 million |
| Cash flows from operating activities | ¥41,181 thousand |
| Cash flows from investing activities | ¥-234,223 thousand |
| Cash flows from financing activities | ¥-65,756 thousand |
| Cash and cash equivalents at end of period | ¥454,218 thousand |
| Full-year earnings forecast | Net Sales ¥2,655 million (YoY +37.9%) / Operating profit ¥278 million (YoY +144.9%) / Ordinary income ¥274 million (YoY +168.8%) / Profit attributable to owners of the parent ¥172 million (YoY +185.9%) |
| Annual Dividend Forecast | ¥0 → ¥0 |
| Segment revenue | Optical business ¥715,361 thousand (YoY +23.0%), Life Science and Equipment Development business ¥131,054 thousand (YoY +23.8%), Other Businesses ¥194,242 thousand (YoY -30.8%) |
| Segment profit | Optical business ¥244,685 thousand (YoY +77.7%), Life Science and Equipment Development business ¥-82,697 thousand, Other Businesses ¥-51,976 thousand |
| Depreciation and amortization | ¥89,401 thousand |
| Impairment loss | － |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥1,590 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥76 thousand |
| Disclosure regarding the going concern assumption | None ("There are no applicable matters.") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No (no eligible attendees) |
| Issued Shares at Period-End | 5,905,500 Shares |
| Treasury Shares at Period-End | 985 Shares |
| Factors Behind Changes in Business Performance | Shipments to domestic synchrotron radiation facilities and shipments of high-margin products lifted revenue and profit in the Optical Business. CellPet® and automated cell culture systems also contributed to revenue. In the Other Business, however, sales of the core products were limited to 1 unit for a domestic customer, and higher raw material prices reduced margins. In the Life Science and Equipment Development Business, selling, general and administrative expenses increased, mainly due to higher research and development expenses. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Shipments to domestic synchrotron radiation facilities and shipments of high-margin products lifted the Optical Business, while CellPet® and automated cell culture systems also contributed to revenue. In the Other Business, however, sales of the core equipment were limited to 1 unit, and higher raw material prices reduced margins. In the Life Science and Equipment Development Business, selling, general and administrative expenses increased, mainly due to higher research and development expenses.